Acetaminophen

Phase 2Recruiting
0 watching 0 views this week Active
52
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Post Operative Analgesia

Conditions

Post Operative Analgesia, Bariatric Surgery, Bariatric Surgery (Gastric Bypass), Bariatric Surgery Patients, Perioperative Analgesia

Trial Timeline

Nov 13, 2024 → May 1, 2026

About Acetaminophen

Acetaminophen is a phase 2 stage product being developed by Johnson & Johnson for Post Operative Analgesia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06658574. Target conditions include Post Operative Analgesia, Bariatric Surgery, Bariatric Surgery (Gastric Bypass).

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (3)

NCT IDPhaseStatus
NCT00261560ApprovedCompleted
NCT06658574Phase 2Recruiting
NCT02911961ApprovedWithdrawn

Competing Products

20 competing products in Post Operative Analgesia

See all competitors
ProductCompanyStageHype Score
PRF110- oily solution (Ropivacaine)PainReformPhase 2
44
PRF110PainReformPhase 2
44
ENZ215 + ProliaAlkem LaboratoriesPhase 3
77
teriparatide + teriparatide + Placebo + Calcium Supplement + Vitamin D SupplementEli LillyPhase 3
77
raloxifene + PlaceboEli LillyApproved
85
MBX 1416 (INN imapextide)MBX BiosciencesPhase 2
47
MBX 1416 (Part A) + MBX 1416 (Part B) + Placebo + MBX 1416 (Part C)MBX BiosciencesPhase 1
28
teriparatide 20 micrograms/day subcutaneous + calcitonin 100 IU/day subcutaneousEli LillyPhase 3
77
teriparatide 20 micrograms/day subcutaneous + salmon calcitonin 100 IU/day subcutaneousEli LillyPhase 3
77
CT-P41 + US-licensed ProliaCelltrionPhase 3
77
LetrozoleChugai PharmaceuticalPhase 2
52
Eldecalcitol soft capsulesChugai PharmaceuticalPre-clinical
23
LetrozoleChugai PharmaceuticalPhase 2
52
LetrozoleChugai PharmaceuticalPhase 2
52
Placebo + DS-5565Daiichi SankyoPre-clinical
23
YM177 + etodolac + PlaceboAstellas PharmaPhase 3
77
QUTENZAAstellas PharmaApproved
85
QutenzaAstellas PharmaPre-clinical
23
CelecoxibAstellas PharmaPre-clinical
23
ASP8477 + PlaceboAstellas PharmaPhase 2
52